Objective We are aiming to study the expression of human
epidermal growth factor 2 (HER2) in gastric carcinoma (GC)
to estimate the susceptibility for target therapy by
trastuzumab hoping to improve the outcome especially in
late stage cases.
Materials and methods This is a retrospective study that
included 50 cases diagnosed as GC in Benha University
hospital. Our study included an examination of the
endoscopic biopsies of 40 cases and the resection
specimens of 10 cases. We assessed HER2 status by
application of immunohistochemistry to all the cases. When
cases were equivocal on immunohistochemistry, we
applied fluorescence in-situ hybridization. The collected
data were statistically analyzed.
Results HER2 was positive in 17 (34%) cases. It was
statistically significant (P